Metode Flushing
Metode Flushing
Additional copies of this guidance document may be requested from the Policy and Regulations
Staff (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish
Place, Rockville MD 20855, and may be viewed on the Internet at https://www.fda.gov/animal-
veterinary, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or
https://www.regulations.gov.
Table of Contents
I. Introduction .......................................................................................................................... 1
II. Background ........................................................................................................................... 1
A. Drug carryover ................................................................................................................ 1
B. Additional regulations covering animal food ............................................................... 3
III. Practices to Prevent Unsafe Contamination from Drug Carryover to Protect
Human and Animal Health.................................................................................................. 3
A. Physical Cleanout ........................................................................................................... 4
B. Flushing............................................................................................................................ 5
C. Sequencing ....................................................................................................................... 5
D. Other Equally Effective Practices ................................................................................. 7
IV. References .............................................................................................................................. 7
i
Contains Nonbinding Recommendations
This guidance represents the current thinking of the Food and Drug Administration (FDA, we, or
Agency) on this topic. It does not establish any rights for any person and is not binding on FDA
or the public. You can use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff
responsible for this guidance as listed on the title page.
I. Introduction
This guidance describes practices available to medicated feed manufacturers to prevent unsafe
contamination from drug carryover into a non-medicated animal feed or a different medicated
feed. This guidance replaces Compliance Policy Guides Sec. 680.500 Unsafe Contamination of
Animal Feed from Drug Carryover and 680.600 Sequencing as a Means to Prevent Unsafe Drug
Contamination in the Production, Storage, and Distribution of Feeds, and includes updates and
additional information. For purposes of this guidance:
• “you” refers to those involved in the manufacturing and distribution of medicated feed.
• “manufacturing and distribution of medicated feed” refers to using equipment to
manufacture, process, pack, hold, and distribute medicated feed, including, for example,
storing, mixing, and conveying.
• “animal feed” or “feed” refers to animal food produced by medicated feed manufacturers.
Such animal food may be referred to in this guidance as “medicated feed,” or “non-
medicated feed,” depending on whether it is formulated to contain a new animal drug.
For convenience, we refer to such new animal drugs as simply “drugs.”
• “drug carryover” refers to the presence of a drug in a subsequent batch of animal feed.
• “unsafe contamination” of an animal feed refers to a degree of contamination, by a drug
approved for a medicated feed use, that poses an unacceptable risk to human or animal
health.
II. Background
A. Drug carryover
1
Contains Nonbinding Recommendations
Drug carryover generally occurs when a drug used in the manufacture of a batch of medicated
feed, for which the drug is approved, gets inadvertently included in a subsequent batch of: (1) a
non-medicated feed, (2) a different medicated feed for which the drug is not approved (e.g.,
medicated feed for another species), or (3) a medicated feed that contains the same drug that can
result in a higher drug level than is stated on the labeling. Drug carryover can occur for various
reasons, including, for example, the use of the same equipment to manufacture both medicated
and non-medicated feed; the design, construction, or inadequate maintenance of feed
manufacturing equipment; poor dust control in a feed mill; inadequate cleanout practices for
manufacturing and distribution equipment between sequential batches of animal feed; or human
error (Refs. 1 and 2).
Ideally, carryover of a drug from one batch to another should always be completely avoided.
However, factors such as the use of shared equipment to manufacture various medicated and
non-medicated feeds, and the design and performance of such equipment used for animal feed
manufacturing may not allow for an absolute avoidance of all batch-to-batch drug carryover.
The current good manufacturing practice (CGMP) regulation for medicated feeds, found in 21
CFR part 225, contains requirements for the manufacturing, processing, packing, and holding of
medicated feed. Some facilities, such as feed mills, are required to have a medicated feed mill
license to manufacture certain medicated feeds (see 21 CFR 510.455(f), 21 CFR 558.4, and 21
CFR 558.5(g)). Section 21 CFR 225.1 applies to all medicated feed mills. Sections 21 CFR
225.10 through 225.115 apply to facilities that are required to hold an approved medicated feed
mill license. Sections 21 CFR 225.120 through 225.202 apply to facilities that are not required
to hold a license.
The CGMP regulation for medicated feeds requires that adequate procedures be established and
used for all equipment used in the manufacture and distribution of medicated feed to avoid
unsafe contamination of medicated and non-medicated feeds with drugs (see 21 CFR 225.65 and
225.165). Therefore, you should focus on preventing unsafe contamination of medicated and
non-medicated feeds by minimizing or, if possible, avoiding drug carryover altogether.
Failure of a facility to comply with the requirements of the CGMP regulation for medicated
feeds (21 CFR part 225), including failure to establish and follow adequate procedures for
cleanout of equipment to avoid unsafe contamination of animal feed, causes medicated feed
manufactured, processed, packed, or held at the facility to be adulterated under section
501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). In addition, if the
medicated feed you manufacture contains a drug that is not approved for use in that animal feed,
the animal feed containing the drug may be considered unsafe within the meaning of section
512(a)(2) of the FD&C Act and adulterated under section 501(a)(6) of the FD&C Act.
When drug carryover from the manufacturing, processing, packing, or holding of medicated feed
results in drug contamination of non-medicated feed, the contaminated animal feed is considered
adulterated under section 402(a)(2)(C)(ii) of the FD&C Act.
For animal drugs used in food-producing animals, FDA establishes a tolerance for the drug
residue in human food as part of the animal drug approval process (see 21 CFR 514.1(b)(7) and
2
Contains Nonbinding Recommendations
part 556). Drug residues detected in excess of an established drug tolerance in food derived from
food-producing animals (e.g., edible animal tissues such as meat, milk, honey, or eggs), or any
residues detected from a drug not approved for use in a food-producing animal, would result in
that human food being adulterated under section 402(a)(2)(C)(ii) of the FD&C Act.
Additional regulations that may be applicable to your operations contain requirements intended
to help ensure the safety of animal food.
The Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive
Controls for Food for Animals regulation, found in 21 CFR part 507, establishes requirements
for baseline safety and sanitation standards (CGMPs) and hazard analysis and risk-based
preventive controls for the manufacturing, processing, packing, and holding of animal food
(which includes pet food, animal feed, and raw materials and ingredients). For guidance on
CGMP requirements in 21 CFR part 507, see our Guidance for Industry (GFI) #235, “Current
Good Manufacturing Practice Requirements for Food for Animals.” 1 For our current thinking on
the hazard analysis and risk-based preventive controls requirements in 21 CFR part 507, see our
GFI #245, “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals.” 2 If you
are subject to 21 CFR part 507, subparts A, C, D, E, and F (the animal food preventive controls
requirements), and you have identified drug carryover as a hazard requiring a preventive control,
you must follow the preventive control requirements in part 507. Compliance with the relevant
requirements of part 507 is used to determine whether your facility’s animal food is adulterated
within the meaning of sections 402(a)(3) and (4) of the FD&C Act (see 21 CFR 507.1(a)).
The Sanitary Transportation of Human and Animal Food regulation is found in 21 CFR part 1,
subpart O. In general, persons involved in the transportation of animal food, including
medicated feed, must comply with the requirements as applicable. For information on this
regulation, see our Small Entity Compliance Guide, “Sanitary Transportation of Human and
Animal Food: What You Need to Know About the FDA Regulation.” 3
III. Practices to Prevent Unsafe Contamination from Drug Carryover to Protect Human
and Animal Health
If you manufacture medicated feed for which an approved medicated feed mill license is
required, you must ensure that all equipment that comes in contact with the active drug
component, feeds in process, or finished medicated feed is subject to all reasonable and effective
procedures to prevent unsafe contamination of manufactured feed (see 21 CFR 225.65(b)).
If you manufacture medicated feed for which an approved medicated feed mill license is not
required, you must establish and use adequate procedures for all equipment used in the
1
https://www.fda.gov/media/97464/download
2
https://www.fda.gov/media/110477/download
3
https://www.fda.gov/media/108944/download
3
Contains Nonbinding Recommendations
production and distribution of medicated feed to avoid unsafe contamination of medicated and
non-medicated feeds (see 21 CFR 225.165).
If you manufacture medicated animal feed and you are subject to 21 CFR part 507, then the
discussion below may suggest practices to use in your implementation of certain requirements of
part 507.
Some factors you should consider when developing your practices to prevent unsafe
contamination from drug carryover include:
• risks to human and/or animal health
• types of animal feed you manufacture (e.g., medicated, requiring a license)
• animal species
• production stages of the animals
• the drugs being used and their levels
• equipment used in your facility
As with all practices used to prevent unsafe contamination from drug carryover in animal feed,
your cleanout practices should be designed to protect the health of the animals consuming the
animal feed and, in the case of food-producing animals, protect human health. There are known
health risks to animals from unsafe contamination of animal feed from drug carryover that you
also should consider when developing your practices. Human health may be at risk if humans
consume a product derived from animals that have consumed animal feed contaminated from
drug carryover. To protect human health, it is important to minimize the potential exposure of
food-producing animals (e.g., animals near slaughter, lactating dairy animals, and laying hens) to
unsafe contamination from drug carryover.
Since every animal feed manufacturing system is unique, the steps you take to establish adequate
practices to prevent unsafe contamination from drug carryover for your operations may be
different from those appropriate for other facilities. You should ensure that all personnel
involved in animal feed scheduling and production understand the practices you establish for
your operations. You should have a plan for reevaluating your practices periodically to ensure
that unsafe contamination from drug carryover does not occur.
The most commonly used practices are described below. Many animal feed manufacturers use a
combination of these methods to suit the requirements of their manufacturing systems,
production schedules, and distribution equipment to prevent unsafe contamination from drug
carryover and thus protect human and animal health.
A. Physical Cleanout
Physical cleanout of manufacturing and distribution equipment used to mix and handle animal
feed is a practice that may include dry-type cleaning (e.g., vacuuming, sweeping, or scraping
equipment used to make dry feed), or wet-type cleaning (e.g., washing equipment used to make
4
Contains Nonbinding Recommendations
liquid feed). Physical cleanout often can be effectively used on a single piece of equipment
when physical cleanout of the entire system is impractical or may not be necessary to ensure
animal feed safety. You should evaluate the entire production line when determining the pieces
of equipment on which to perform physical cleanout. Physical cleanout is an important practice
used to prevent unsafe contamination from drug carryover.
B. Flushing
C. Sequencing
The following list provides factors you should consider when designing your sequencing practice
to prevent unsafe contamination from drug carryover and to protect human and animal health.
You should consider your specific manufacturing system when designing a sequencing practice.
This is not an all-inclusive list.
• Animal feed for animals near slaughter, lactating dairy animals, or laying hens should not
be manufactured and handled on the same equipment immediately following the
manufacture of medicated feeds containing drugs requiring a withdrawal period or drugs
not approved for use in those species and production classes, unless adequate cleanout
5
Contains Nonbinding Recommendations
• Animal feed that cannot contain a drug requiring a withdrawal period (e.g., feed intended
for animals near slaughter, lactating dairy animals, or laying hens) should be
manufactured first in the sequence. Medicated feed with the highest potential to cause
unsafe contamination from drug carryover should be manufactured last in the sequence,
followed by adequate cleanout of the system before restarting the
manufacturing/processing/sequencing cycle.
• Medicated feed containing drugs that could cause an unsafe residue in an animal’s edible
tissues if consumed by finishing animals should be manufactured after other animal feed.
For example, non-medicated swine finishing feed should be manufactured before a
medicated feed.
• When you are manufacturing multiple lots of medicated feed containing the same drug,
the sequence should be scheduled to produce the feed containing the highest
concentration of the drug first and feed containing the lowest concentration of the drug
last. The feed with the lowest concentration of the drug in the sequence could then be
followed by a non-medicated feed for the same species or a medicated feed containing
that same drug for another species.
• Swine are sensitive to the interaction of the drug tiamulin with a polyether ionophore
drug (e.g., narasin); the interaction could result in ionophore toxicity in swine (Ref. 4).
To avoid this interaction, you should manufacture other animal feeds in between the
manufacture of a feed containing a polyether ionophore and a swine feed containing
tiamulin, or conduct a physical cleanout.
• Pre-ruminating calves are sensitive to salinomycin; ingestion of this drug may result in
severe or fatal effects in pre-ruminating calves (Ref. 5). Pre-ruminating calf feed (e.g.,
4
Drugs approved for use in animal feed are placed into one of two categories: Category I or Category II. Category I
drugs require no withdrawal period at the lowest use level in each major species for which they are approved (or are
approved for use only in minor species). Category II drugs require a withdrawal period at their lowest approved use
level for at least one major species, or are regulated on a “no-residue” basis or with a zero tolerance (21 CFR
558.3(b)).
6
Contains Nonbinding Recommendations
You may use alternative, equally effective practices to prevent unsafe contamination of animal
feed from drug carryover other than those discussed in this guidance. We encourage you to
contact the Center for Veterinary Medicine (CVM), Division of Food Compliance at
AskCVM@fda.hhs.gov to discuss alternatives to the practices presented in this guidance that you
would like to use.
IV. References
1. Food and Drug Administration. 2018. Warning Letter, Gilman Cooperative Creamery
Association, October 10, 2018. Accessed Sept. 30, 2022. https://www.fda.gov/inspections-
compliance-enforcement-and-criminal-investigations/warning-letters/gilman-cooperative-
creamery-association-563944-10052018.
2. Food and Drug Administration. 2017. Warning Letter, Burkmann Industries Inc., August 29,
2017. Accessed Sept. 30, 2022. https://www.fda.gov/inspections-compliance-enforcement-
and-criminal-investigations/warning-letters/burkmann-industries-inc-533330-08292017.
3. Matsuoka, T., et.al. 1996. “Review of Monensin in Horses.” Journal of Equine Veterinary
Science. Volume 16, Number 1: 8-15.
4. Carpenter, Jane A., et. al. 2005. “Tiamulin and narasin toxicosis in nursery pigs.” Journal of
Swine Health and Production. Volume 13, Number 6: 333-336. Accessed Sept. 30, 2022.
https://www.aasv.org/shap/issues/v13n6/v13n6p333.pdf.
5. Huyben, M.W.C., et.al. 2001. “Salinomycin poisoning in veal valves.” The Veterinary
Record. August 11. 2001: 183-184.